40,800 Shares in Repligen Corporation $RGEN Bought by Weitz Investment Management Inc.

Weitz Investment Management Inc. acquired a new position in Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 40,800 shares of the biotechnology company’s stock, valued at approximately $5,567,000. Weitz Investment Management Inc. owned approximately 0.07% of Repligen as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in shares of Repligen during the 1st quarter worth $262,000. Jones Financial Companies Lllp increased its holdings in shares of Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after purchasing an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after purchasing an additional 20,375 shares in the last quarter. Bank of Nova Scotia lifted its stake in shares of Repligen by 88.0% in the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after purchasing an additional 14,860 shares during the period. Finally, Daiwa Securities Group Inc. lifted its stake in shares of Repligen by 29.7% in the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock valued at $3,880,000 after purchasing an additional 7,148 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. HSBC decreased their price target on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. boosted their target price on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Barclays upped their target price on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, Citigroup upgraded Repligen to a “buy” rating in a research report on Tuesday, July 7th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $166.43.

Repligen Price Performance

Repligen stock opened at $181.13 on Friday. The stock has a market capitalization of $10.22 billion, a P/E ratio of 248.12, a P/E/G ratio of 3.31 and a beta of 1.03. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $188.73. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The firm’s 50-day moving average is $147.16 and its two-hundred day moving average is $131.88.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Insider Buying and Selling

In other Repligen news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.60% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.